MediSieve
Chris Jones has a diverse and extensive work experience spanning various roles and positions in the healthcare industry. Chris currently serves as the Executive Chairman of Global Access Dx (GADx) and Chairman of FREEHAND - OR Productivity Ltd. Chris is also the Non-Executive Director and Special Advisor of MediSieve Limited, Non-Executive Director of Causeway Therapeutics, Health Enterprise East, and Deltex Medical. Previously, they held the role of Executive Chairman at Elasmogen Ltd from 2016 to 2023. Before that, they served as the CEO of GlySure Ltd and Tensys Medical, where they also held the position of COO. Chris also gained valuable experience as the VP of Marketing at Tyco Healthcare, Nellcor Critical Care Division.
Chris Jones attended Yale University from 1985 to 1989, where they pursued a Bachelor of Science degree in Molecular Biophysics and Biochemistry.
This person is not in any teams
MediSieve
1 followers
MediSieve is a multi-award-winning medical device company developing Magnetic Blood Filtration (MBF), a platform technology for the treatment of blood-borne diseases by physically removing disease relevant targets directly from a patient’s bloodstream. MBF is an extracorporeal technology, similar to dialysis. A patient's blood is continuouslycirculated through an external blood loop containing the MediSieve system. Targeted magnetic particles (TB-MPs) are infused into the loop, binding specifically to disease-relevant targets in the patient's blood. The blood then flows through a magnetic filter which captures the particles and bound targets and the remainder of the blood returns to the patient unaffected; the TB-MPs never enter the patient’s body.MediSieve is based at the Imperial Incubator in White City, London. It has dedicated workshop and laboratory facilities (including capacity for ELISAs, Flow Cytometry and human blood testing) in which products are developed and validated.